Business Wire

Allurion Technologies Unveils Transformed Allurion™ Weight Loss Program and New Corporate Brand

Share

Allurion Technologies announced today two major milestones with the launch of the transformed Allurion Weight Loss Program and new worldwide brand for the company and its program.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005001/en/

Allurion began commercial sales of its flagship Elipse® Gastric Balloon in 2016. Over the past five years, the company has treated over 50,000 patients across 40 countries. In that time, the company’s weight loss solution has evolved from a single device to a comprehensive program that combines medical, digital, and nutritional approaches to jumpstart weight loss and form lifelong healthy habits.

The new Allurion Program unveiled today features:

  • The Allurion® Balloon, rebranded to reflect its synergistic role with other features in the program
  • The Allurion® Virtual Care Suite, enabling end-to-end patient management through the Allurion Health Tracker, Connected Scale, and App
  • Allurion Insights, offering providers real-time patient analytics and telehealth features

The Allurion Balloon is the world’s first and only procedureless™ medical device for weight loss that leads to 10-15% total body weight loss in approximately 16 weeks. Over 50,000 patients have been treated with the Allurion Balloon, and its re-branding not only reflects its role within the Allurion Program but also device improvements that have been made to optimize the patient and provider experience.

The Allurion Balloon works hand-in-hand with the Allurion® Virtual Care Suite. The Virtual Care Suite includes tools for the patient and the provider to have a 360-degree weight loss experience designed to deliver lifelong results. The patient receives the Allurion Health Tracker, Connected Scale, and App to track, monitor and support their progress while providing real-time data to their healthcare team. Allurion Insights seamlessly integrates this data with the provider and facilitates end-to-end patient management by providing real-time patient analytics and telehealth features.

The new branding launched today includes new messaging, identity, logos, and other design elements that have been incorporated across all products to deliver a consistent and unified experience to patients and providers around the globe.

“The launch of our transformed Allurion Program and our new branding is the culmination of an initiative we began over a year ago to reimagine the future of weight loss and evolve from a company that offers a product to one that offers a revolutionary experience that delivers lifelong results,” said Shantanu Gaur, M.D., co-founder and CEO of Allurion Technologies. “We worked closely with our patients and providers to develop an experience that meets their needs, and we look forward to seeing the positive impact it will have on patient outcomes around the world.”

About Allurion Technologies

Allurion Technologies is dedicated to ending obesity. The Allurion Program is a 360-degree weight loss experience featuring the Allurion Balloon, the world’s first and only swallowable, procedureless gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Connected Scale, Health Tracker, and App, and Allurion Insights. Learn more about Allurion online at www.allurion.com. Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Whitney Cypes
+1 (408)-547-7531

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IC Markets Records Highest Ever Monthly Trading Volume of USD 1.016 Trillion in November7.12.2021 02:29:00 CET | Press release

IC Markets has recorded its highest ever monthly trading volume, following a surge in trading volume across all asset classes in November. According to IC Markets the record month is a result of its product diversification, growth into new markets, an increased client retention rate and optimum trading conditions which led to clients taking advantage of high volatility in the markets. The results follow last year’s unprecedented growth across the global retail trading industry, with IC Markets reporting $9.32 trillion in trading volume for the year. The trading volumes for November eclipsed the previous high of $1 trillion achieved in March this year. IC Markets CEO Andrew Budzinski commented, “We are delighted to be bringing more traders across a growing number of markets a greater choice of trading instruments so they can diversify their portfolio whilst taking advantage of the optimum trading conditions.” “Our traders are staying with us to take advantage of the highly competitive s

Conviva Teams With Experian to Expand Audience Measurement Capabilities for Streaming Publishers7.12.2021 00:00:00 CET | Press release

Conviva, the continuous measurement platform for streaming media, has teamed with Experian, the leading global information services company, to provide streaming publishers and their ecosystem partners with the industry’s most advanced audience segmentation data, a key step towards solving the streaming industry’s global measurement challenge. The combination of Conviva’s first-party, census-level streaming data and Experian’s unparalleled demographic data empowers publishers to easily provide advertisers with the most detailed and accurate audience insights available, including audience content preferences, viewer behavior patterns, ad exposures and more. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211206005840/en/ Experian + Conviva (Graphic: Business Wire) The solution is bolstered by the integration of Experian marketing data into Conviva’s newly expanded streaming audience measurement platform, which includes Stream

CSC Reaches Conditional Agreement to Acquire Intertrust N.V.6.12.2021 15:45:00 CET | Press release

CSC, the world’s leading provider of business, legal, tax, and digital brand services, announces a conditional agreement has been reached on a recommended public offer for all issued and outstanding ordinary shares of Intertrust. The combination of CSC and Intertrust creates a clear and differentiated leader for clients on an international scale, built on the combined strengths of each other’s global teams with complementary geographic and service offerings. Founded in 1899, with headquarters in Wilmington, Delaware, USA, and with 3,000 employees in 13 countries across the globe, CSC is the trusted partner for more than 180,000 corporate clients—including 90% of the Fortune 500®—as well as nearly 10,000 law firms and more than 3,000 financial institutions. CSC’s success is built on its ability to provide its clients with best-in-class solutions to efficiently manage and enable key business processes. Since 2002, CSC has made more than 25 strategic acquisitions, building a solid reputat

Wipro and Celonis Launch Supply Chain Command Center Solution6.12.2021 14:24:00 CET | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, and Celonis, the global leader in execution management, today announced the launch of the Supply Chain Command Center to help organizations drive supply-chain transformation. The solution enables companies to automatically identify and fix process bottlenecks and inefficiencies, gain powerful business insights, open new growth opportunities, manage risks and maintain business continuity even in disruptive times. It improves the supply-chain efficiency by working across the four stages - planning, sourcing, developing and delivering. The Supply Chain Command Center combines a range of business-critical capabilities, from process KPI benchmarks to process optimization in transformation programs. Enterprises can leverage ready-to-use models for process maturity level assessment, custom code analysis, and automation opportunities. The solution is of

Local Loyal, Spice Seeking, Mindful Mixologists - These Are the Spirits Consumers of 2022, According to the Annual Bacardi Cocktail Trends Report6.12.2021 13:00:00 CET | Press release

Bacardi Limited, theworld's largest privately-held spirits company, releases its third annual Bacardi Cocktail Trends Report, looking ahead at the key trends impacting the business of cocktails in 2022. The report is created in collaboration withThe Future Laboratory (TFL) and draws from Bacardi-led and external research to unveil the undercurrents transforming everything from drinks desired, flavor expectations, and imbibing occasions through to ethical action and ways of creating cocktails. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211206005158/en/ The third annual Bacardi Cocktail Trends Report spotlights the macro-trends defining how, what, where, and why consumers are sipping spirits in 2022. (Graphic: Business Wire) “As 2022 brings new perspective, people are coming together with a strong desire to ‘Make Moments Matter’. At Bacardi, we are driven by this purpose – with a family of premium spirit brands that are un

Galderma Announces New Data Demonstrating the Positive Anti-inflammatory Effect and Mode of Action of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis6.12.2021 10:00:00 CET | Press release

Galderma today announced that the Journal of Allergy and Clinical Immunology has published gene expression data that demonstrate the positive anti-inflammatory effect and mode of action of nemolizumab in patients with moderate to severe Prurigo Nodularis (PN), confirming the potential of nemolizumab as a major player in the treatment of PN, effectively reducing both pruritus and severity of skin lesions in PN patients. “Transcriptome data is an important step in validating the therapeutic effect of nemolizumab through a deeper understanding of the mode of action at a cellular level. With these data, we are advancing dermatology and contributing to improving our understanding of PN. These data emphasize that nemolizumab may have a key role to play for patients with moderate to severe PN. This will be confirmed by our ongoing nemolizumab Phase 3 studies in PN.” Dr. Baldo Scassellati Sforzolini Global Head of R&D, GALDERMA PN is a rare, potentially debilitating, chronic skin condition wit

iProov and Eurostar Launch Trial to Provide Contactless Travel at London St Pancras International6.12.2021 08:00:00 CET | Press release

iProov, the world leader in biometric face authentication technology, and Eurostar, the high-speed passenger rail service linking the UK with mainland Europe, have announced that their trial of a contactless fast-track service, SmartCheck, is now live. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211205005029/en/ iProov and Eurostar announce contactless travel trial is live at London St Pancras International (Photo: Business Wire) SmartCheck enables passengers to complete secure ticket verification and UK exit check on their mobile devices prior to travel. As part of the trial, Business Premier and Carte Blanche ticket holders will be able to scan their identity documentation using their iPhones before arriving at the station, completing a brief biometric face scan to verify that they are the genuine holder of the identity document. The biometric face verification, which uses iProov’s Genuine Presence Assurance technology,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom